{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = (2''S'')-6-Amino-2-<nowiki>[[</nowiki>(2''S'')-2-<nowiki>[[</nowiki>(2''S'')-2-<nowiki>[[</nowiki>(2''S'')-2-<nowiki>[[</nowiki>(2''R'')-2-<nowiki>[[</nowiki>(2''R'')-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1''H''-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
| image = Pralmorelin.svg
| width = 250

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = Oral, intravenous

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref = 
| CAS_number = 158861-67-7
| CAS_supplemental = 
| ATC_prefix = 
| ATC_suffix = 
| PubChem = 6852372
| IUPHAR_ligand = 1092
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 5293451

<!--Chemical data-->
| C=45 | H=55 | N=9 | O=6
| molecular_weight = 817.9749 g/mol
| smiles = C[C@H](C(=O)N[C@H](CC1=CC2=CC=CC=C2C=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@H](CC5=CC=CC=C5)C(=O)N[C@@H](CCCCN)C(=O)N)N
|  StdInChI = 1S/C45H55N9O6/c1-27(47)41(56)52-38(24-30-19-20-31-14-6-7-15-32(31)22-30)43(58)50-28(2)42(57)53-39(25-33-26-49-35-17-9-8-16-34(33)35)45(60)54-37(23-29-12-4-3-5-13-29)44(59)51-36(40(48)55)18-10-11-21-46/h3-9,12-17,19-20,22,26-28,36-39,49H,10-11,18,21,23-25,46-47H2,1-2H3,(H2,48,55)(H,50,58)(H,51,59)(H,52,56)(H,53,57)(H,54,60)/t27-,28+,36+,37-,38-,39+/m1/s1
|  StdInChIKey = HRNLPPBUBKMZMT-RDRUQFPZSA-N
| synonyms = D-Alanyl-3-(naphthalen-2-yl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide
}}

'''Pralmorelin''' ([[International Nonproprietary Name|INN]]) (brand name '''GHRP Kaken 100'''; former developmental code names '''KP-102''', '''GPA-748''', '''WAY-GPA-748'''), also known as '''pralmorelin hydrochloride''' ([[Japanese Accepted Name|JAN]]) and '''pralmorelin dihydrochloride''' ([[United States Adopted Name|USAN]]), as well as, notably, '''growth hormone-releasing peptide 2''' ('''GHRP-2'''), is a [[growth hormone secretagogue]] (GHS) used as a [[diagnostic agent]] that is marketed by [[Kaken Pharmaceutical]] in [[Japan]] in a single-dose formulation for the assessment of [[growth hormone deficiency]] (GHD).<ref name="Graul2006">{{cite journal|last1=Graul|first1=Ann I.|last2=Prous|first2=J.R.|title=The Year's New Drugs: A Historical and Research Perspective on the 41 New Products that Reached their First Markets in 2005|journal=Drug News & Perspectives|volume=19|issue=1|year=2006|page=33|issn=0214-0934|publisher=Prous Science|url=https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=3&p_RefId=2990&p_IsPs=Y}}</ref><ref name="MoulinBrunel2014">{{cite journal|last1=Moulin|first1=Aline|last2=Brunel|first2=Luc|last3=Verdie|first3=Pascal|last4=Gavara|first4=Laurent|last5=Martinez|first5=Jean|last6=Fehrentz|first6=Jean-Alain|title=Ghrelin Receptor Ligands: Design and Synthesis of Pseudopeptides and Peptidomimetics|journal=Current Chemical Biology|volume=7|issue=3|year=2014|pages=254–270|issn=2212-7968|doi=10.2174/2212796807999131128125920}}</ref><ref name="JamesonGroot2015">{{cite book|author1=J. Larry Jameson|author2=Leslie J. De Groot|title=Endocrinology: Adult and Pediatric: Expert Consult - Online|url=https://books.google.com/books?id=xmLeBgAAQBAJ&pg=PT1366|date=25 February 2015|publisher=Elsevier Health Sciences|isbn=978-0-323-32195-2|pages=1366–}}</ref>

Pralmorelin is an [[oral administration|orally-active]], [[Organic compound#Synthetic compounds|synthetic]] [[peptide]] [[drug]], specifically, an [[structural analog|analogue]] of [[met-enkephalin]], with the [[amino acid sequence]] <small>D</small>-Ala-<small>D</small>-(β-naphthyl)-Ala-Ala-Trp-<small>D</small>-Phe-Lys-NH<sub>2</sub>.<ref name="MoulinBrunel2014" /><ref name="AdisEditorial2004">{{cite journal | author=Adis Editorial | title=Pralmorelin | journal=Drugs in R & D | publisher=Springer International Publishing | volume=5 | issue=4 | year=2004 | pages=236–239 | doi=10.2165/00126839-200405040-00011 | url=https://link.springer.com/article/10.2165/00126839-200405040-00011}}</ref> It acts as a [[growth hormone secretagogue receptor|ghrelin/growth hormone secretagogue receptor]] (GHSR) [[agonist]], and was the first of this class of drugs to be introduced clinically.<ref name="MoulinBrunel2014" /><ref name="JamesonGroot2015" /> Acute administration of the drug markedly increases the levels of [[Blood plasma|plasma]] [[growth hormone]] (GH)<ref name="AdisEditorial2004" /><ref name="pmid15646371">{{cite journal | vauthors = Furuta S, Shimada O, Doi N, Ukai K, Nakagawa T, Watanabe J, Imaizumi M | title = General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide | journal = Arzneimittelforschung | volume = 54 | issue = 12 | pages = 868–80 | year = 2004 | pmid = 15646371 | doi = 10.1055/s-0031-1297042 | url = http://www.thieme-connect.com/DOI/DOI?10.1055/s-0031-1297042}}</ref> and reliably induces sensations of [[hunger]] and increases [[food intake]] in humans.<ref name="MüllerNogueiras2015">{{cite journal|last1=Müller|first1=T.D.|last2=Nogueiras|first2=R.|last3=Andermann|first3=M.L.|last4=Andrews|first4=Z.B.|last5=Anker|first5=S.D.|last6=Argente|first6=J.|last7=Batterham|first7=R.L.|last8=Benoit|first8=S.C.|last9=Bowers|first9=C.Y.|last10=Broglio|first10=F.|last11=Casanueva|first11=F.F.|last12=D'Alessio|first12=D.|last13=Depoortere|first13=I.|last14=Geliebter|first14=A.|last15=Ghigo|first15=E.|last16=Cole|first16=P.A.|last17=Cowley|first17=M.|last18=Cummings|first18=D.E.|last19=Dagher|first19=A.|last20=Diano|first20=S.|last21=Dickson|first21=S.L.|last22=Diéguez|first22=C.|last23=Granata|first23=R.|last24=Grill|first24=H.J.|last25=Grove|first25=K.|last26=Habegger|first26=K.M.|last27=Heppner|first27=K.|last28=Heiman|first28=M.L.|last29=Holsen|first29=L.|last30=Holst|first30=B.|last31=Inui|first31=A.|last32=Jansson|first32=J.O.|last33=Kirchner|first33=H.|last34=Korbonits|first34=M.|last35=Laferrère|first35=B.|last36=LeRoux|first36=C.W.|last37=Lopez|first37=M.|last38=Morin|first38=S.|last39=Nakazato|first39=M.|last40=Nass|first40=R.|last41=Perez-Tilve|first41=D.|last42=Pfluger|first42=P.T.|last43=Schwartz|first43=T.W.|last44=Seeley|first44=R.J.|last45=Sleeman|first45=M.|last46=Sun|first46=Y.|last47=Sussel|first47=L.|last48=Tong|first48=J.|last49=Thorner|first49=M.O.|last50=van der Lely|first50=A.J.|last51=van der Ploeg|first51=L.H.T.|last52=Zigman|first52=J.M.|last53=Kojima|first53=M.|last54=Kangawa|first54=K.|last55=Smith|first55=R.G.|last56=Horvath|first56=T.|last57=Tschöp|first57=M.H.|title=Ghrelin|journal=Molecular Metabolism|volume=4|issue=6|year=2015|pages=437–460|issn=2212-8778|doi=10.1016/j.molmet.2015.03.005}}</ref>

Pralmorelin was also under investigation for the treatment of GHD and [[short stature]] ([[pituitary dwarfism]]), and made it to [[Phases of clinical research#Phase II|phase II]] [[clinical trial]]s for these indications, but was ultimately never marketed for them.<ref name="AdisEditorial2004" /> This may be because the ability of pralmorelin to increase plasma GH levels is significantly lower in people with GHD relative to healthy individuals.<ref name="AdisEditorial2004" />

==See also==
* [[Anamorelin]]
* [[Capromorelin]]
* [[Examorelin|Examorelin (hexarelin)]]
* [[GHRP-6|GHRP-6 (SKF-110679)]]
* [[Ibutamoren|Ibutamoren (MK-677)]]
* [[Ipamorelin]]
* [[Macimorelin]]
* [[Relamorelin]]
* [[SM-130,686]]
* [[Tabimorelin]]

==References==
{{Reflist|2}}


{{Diagnostic agents}}
{{GH/IGF-1 axis signaling modulators}}

[[Category:Ghrelin receptor agonists]]
[[Category:Growth hormone secretagogues]]
[[Category:Hormonal agents]]
[[Category:Peptides]]
[[Category:World Anti-Doping Agency prohibited substances]]
[[Category:Abandoned drugs]]


{{systemic-hormonal-drug-stub}}